title: Evolution in pharmacologic thinking around the natural analgesic palmitoylethanolamide: from nonspecific resistance to PPAR-α agonist and effective nutraceutical.
abstract: The history of development of new concepts in pharmacology is a highly interesting topic. This review discusses scientific insights related to palmitoylethanolamide (PEA) and its progression over a period of six decades, especially in light of the work of the science sociologists, Ludwig Fleck and Thomas Kuhn. The discovery of the cannabis receptors and the nuclear peroxisome proliferator-activated receptors was the beginning of a completely new understanding of many important homeostatic physiologic mechanisms in the human body. These discoveries were necessary for us to understand the analgesic and anti-inflammatory activity of PEA, a body-own fatty amide. PEA is a nutrient known already for more than 50 years. PEA is synthesized and metabolized in animal cells via a number of enzymes and has a multitude of physiologic functions related to metabolic homeostasis. PEA was identified in the 1950s as a therapeutic principle with potent anti-inflammatory properties. Since 1975, its analgesic properties have been noted and explored in a variety of chronic pain states. Since 2008, PEA has been available as a nutraceutical under the brand names Normast® and PeaPure®. A literature search on PEA meanwhile has yielded over 350 papers, all referenced in PubMed, describing the physiologic properties of this endogenous modulator and its pharmacologic and therapeutic profile. This review describes the emergence of concepts related to the pharmacologic profile of PEA, with an emphasis on the search into its mechanism of action and the impact of failing to identify such mechanism in the period 1957-1993, on the acceptance of PEA as an anti-inflammatory and analgesic compound.
authors: Department of Pharmacology, University of witten/Herdecke, witten, Germany.
authors: Jan M Keppel
authors: JM
authors: Hesselink
keywords: nutraceutical; palmitoylethanolamide; paradigm; peroxisome proliferator-activated receptor-alpha; science; sociology
references: Trends Neurosci. 1996 Nov;19(11):514-20
references: 8931279
references: Lancet. 1975 Sep 20;2(7934):558
references: 51386
references: Br J Pharmacol. 2002 Jun;136(3):452-8
references: 12023948
references: Br J Pharmacol. 1998 Oct;125(3):533-41
references: 9806337
references: Lancet. 1951 May 19;1(6664):1085-8
references: 14832973
references: Curr Med Chem. 1999 Aug;6(8):757-73
references: 10469890
references: J Neurol Sci. 1995 Jun;130(2):119-27
references: 8586974
references: Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3376-80
references: 7724569
references: Agents Actions. 1993;39 Spec No:C145-7
references: 7505999
references: Lancet. 1956 Apr 21;270(6921):464-6
references: 13307964
references: Cesk Pediatr. 1977 Jun;32(6):365-9
references: 902351
references: Eur J Clin Pharmacol. 1974 Oct 4;7(6):415-9
references: 4439865
references: Neoplasma. 1975;22(5):519-24
references: 1196434
references: Prog Lipid Res. 1990;29(1):1-43
references: 2087478
references: Brain Res. 2012 Oct 5;1477:45-58
references: 23046519
references: Biochem Pharmacol. 1973 Oct 15;22(20):2529-36
references: 4763589
references: Neuropsychopharmacology. 2012 Jun;37(7):1784-92
references: 22414817
references: J Leukoc Biol. 2012 Jun;91(6):911-20
references: 22469754
references: Toxicon. 1972 Aug;10(5):485-90
references: 4561079
references: CNS Neurol Disord Drug Targets. 2011 Dec;10(8):916-20
references: 22229320
references: Experientia. 1973 May 1;29(1):67-8
references: 4729458
references: Arch Immunol Ther Exp (Warsz). 1977;25(5):655-61
references: 202215
references: Neoplasma. 1975;22(6):625-30
references: 1214924
references: Therapie. 1967 Nov-Dec;22(6):1241-6
references: 5587468
references: Biochim Biophys Acta. 1982 Aug 18;712(2):342-55
references: 7126608
references: Science. 1992 Dec 18;258(5090):1946-9
references: 1470919
references: J Exp Med. 1954 Nov 1;100(5):425-35
references: 13211905
references: Pain. 2013 Sep;154(9):1649-1658
references: 23707281
references: J Neuroinflammation. 2012 Mar 09;9:49
references: 22405189
references: Brain Res. 1977 Sep 16;133(2):358-66
references: 902100
references: Lancet. 1975 Jan 25;1(7900):198-200
references: 47424
references: J Pharmacol Exp Ther. 2008 Jul;326(1):12-23
references: 18367664
references: Nature. 1990 Oct 18;347(6294):645-50
references: 2129546
references: Eur J Pharmacol. 2009 May 21;610(1-3):75-80
references: 19289116
references: Cas Lek Cesk. 1978 Aug 18;117(33):1030-4
references: 699010
references: Acta Physiol Acad Sci Hung. 1971;39(4):395-400
references: 5119194
references: Cesk Epidemiol Mikrobiol Imunol. 1978 Feb;27(1):38-45
references: 149599
references: Biochim Biophys Acta. 1999 Sep 22;1440(2-3):266-74
references: 10521710
references: J Lab Clin Med. 1958 May;51(5):709-14
references: 13539486
references: J Pain Res. 2012;5:437-42
references: 23166447
references: Mediators Inflamm. 2013;2013:328797
references: 23533304
references: J Biol Chem. 1965 Mar;240:1019-24
references: 14284696
references: J Neuroinflammation. 2013 Feb 01;10:20
references: 23374874
references: Biochem Biophys Res Commun. 1979 Sep 27;90(2):628-33
references: 508325
references: Exp Neurol. 2010 Jul;224(1):23-36
references: 20353776
references: Boll Soc Ital Biol Sper. 1968 May 15;44(9):809-13
references: 5699335
references: Cas Lek Cesk. 1979 Oct 12;118(40-41):1249-51
references: 527003
references: Brain Behav Immun. 2012 Nov;26(8):1310-21
references: 22884901
references: J Neurosci. 2012 Sep 12;32(37):12735-43
references: 22972997
references: J Hyg Epidemiol Microbiol Immunol. 1979;23(1):11-24
references: 392005
references: Int J Inflam. 2013;2013:151028
references: 24066256
references: J Med Chem. 2005 Aug 11;48(16):5059-87
references: 16078824